Home › Companies › XENON PHARMACEUTICALS INC. › 2023-2024

XENON PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and XENON PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 13Reported items
  • 224Asset managers
  • 2,526Fund votes
  • 2024-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore XENON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by XENON PHARMACEUTICALS INC.

These tallies are XENON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

XENON PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Dawn Svoronos 61,455,3584,487,857-- --2,559,642 Majority: yes
Elect Director: Gillian Cannon 65,895,89147,324-- --2,559,642 Majority: yes
Elect Director: Steven Gannon 65,709,645233,570-- --2,559,642 Majority: yes
Elect Director: Elizabeth Garofalo 62,307,3763,635,839-- --2,559,642 Majority: yes
Elect Director: Justin Gover 65,932,08311,132-- --2,559,642 Majority: yes
Elect Director: Patrick Machado 63,197,8192,745,396-- --2,559,642 Majority: yes
Elect Director: Ian Mortimer 65,768,424174,791-- --2,559,642 Majority: yes
Elect Director: Gary Patou 64,901,6601,041,555-- --2,559,642 Majority: yes
Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay"). 63,950,0641,979,40213,742 --2,559,642 Majority: yes
Proposal Three – Amendments to Amended and Restated 2014 Equity Plan. 63,107,1282,823,05613,030 --2,559,643 Majority: yes
Proposal Four – Appointment of Auditor. 66,736,364---- 1,766,4930 Majority: yes
Proposal Five – Remuneration of Auditor. 65,671,700390,40613,121 --2,427,630 Majority: yes

Source: XENON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-05 — read the filing on EDGAR.

How asset managers voted at the XENON PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 224 asset managers that disclosed a XENON PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of XENON PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's named executive officers

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 12 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 63,950,064AGAINST: 1,979,402

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay").”): 63,950,064 for, 1,979,402 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 85% for, 3% against (87% of the company cast a for/against vote).

The 222 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%
FOR: 98.1%AGAINST: 1.8%ABSTAIN: 0.0%NOT VOTED: 0.0%
Largest asset managers voting on “Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's ” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity12,867,2100 00For
Capital Group10,314,0620 00For
Avoro Capital Advisors LLC4,192,5500 00For
Wellington3,648,6150 00For
DRIEHAUS CAPITAL MANAGEMENT LLC3,217,2990 00For
Vanguard2,877,8760 00For
Polar Capital Holdings Plc2,508,7830 00For
Paradigm Biocapital Advisors LP2,445,3860 00For
T. Rowe Price2,228,1150 00For
COMMODORE CAPITAL LP2,167,7930 00For
BlackRock1,924,4040 00For
AllianceBernstein1,787,9700 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,749,5550 00For
Federated Hermes1,469,8000 00For
BRAIDWELL LP1,308,6770 00For
First Light Asset Management, LLC1,278,1550 00For
Rock Springs Capital Management LP1,255,5770 00For
PICTET ASSET MANAGEMENT SA1,230,3280 00For
Invesco1,172,6220 00For
Loomis Sayles1,074,4810 00For
Janus Henderson937,0470 00For
LORD, ABBETT & CO. LLC792,9070 00For
Affinity Asset Advisors, LLC772,8160 00For
Avidity Partners Management LP710,0000 00For
TimesSquare Capital Management, LLC649,6780 00For

Showing the 25 largest of 222 asset managers. See all 222 in the interactive database.

2. Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Equity Incentive Plan, including to increase the maximum number of Common Shares available for issuance thereunder by 5,200,000

COMPENSATIONMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 63,107,128AGAINST: 2,823,056

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Three – Amendments to Amended and Restated 2014 Equity Plan.”): 63,107,128 for, 2,823,056 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 84% for, 4% against (87% of the company cast a for/against vote).

The 71 asset managers below cast 97% of the shares they voted on this item FOR (26,426,787 for, 698,228 against).

FOR 97%
FOR: 26,426,787 (97.4%)AGAINST: 698,228 (2.6%)ABSTAIN: 9,641 (0.0%)
Largest asset managers voting on “Amendment to the Amended and Restated 2014 Plan Approve certain amendments to the Amended and Restated 2014 Eq” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
First Light Asset Management, LLC1,278,1550 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM94,797326,932 00Against
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 9,6410For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam0238,670 00Against
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

3. Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditor of the Corporation

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 65,671,700AGAINST: 390,406

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Five – Remuneration of Auditor.”): 65,671,700 for, 390,406 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 87% for, 0.6% against (88% of the company cast a for/against vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (25,819,874 for, 0 against).

FOR 99.9%
FOR: 25,819,874 (100.0%)ABSTAIN: 9,641 (0.0%)
Largest asset managers voting on “Remuneration of Auditor Authorize the Audit Committee of the board of directors of the Corporation to fix the ” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 9,6410For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meeting of the Corporation or until their successors are duly elected

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 66,736,364WITHHELD: 1,766,493

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Four – Appointment of Auditor.”): 66,736,364 for, 1,766,493 withheld, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 88% for, 2% withheld (91% of the company cast a for/withheld vote).

The 69 asset managers below cast 100% of the shares they voted on this item FOR (25,787,104 for, 0 against).

FOR 99.8%
FOR: 25,787,104 (99.8%)ABSTAIN: 41,677 (0.2%)
Largest asset managers voting on “Appointment of Auditor Appoint KPMG LLP as the Corporation's auditor to hold office until the next annual meet” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3570 9,6410For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

5. Election of Directors: Dawn Svoronos

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 61,455,358AGAINST: 4,487,857

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dawn Svoronos”): 61,455,358 for, 4,487,857 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 81% for, 6% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.4% of the shares they voted on this item FOR (25,686,549 for, 142,232 against).

FOR 99.4%
FOR: 25,686,549 (99.4%)AGAINST: 142,232 (0.6%)
Largest asset managers voting on “Election of Directors: Dawn Svoronos” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

6. Election of Directors: Elizabeth Garofalo

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 62,307,376AGAINST: 3,635,839

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 62,307,376 for, 3,635,839 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 83% for, 5% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.8% of the shares they voted on this item FOR (25,792,108 for, 36,673 against).

FOR 99.8%
FOR: 25,792,108 (99.9%)AGAINST: 36,673 (0.1%)
Largest asset managers voting on “Election of Directors: Elizabeth Garofalo” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

7. Election of Directors: Gary Patou

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 64,901,660AGAINST: 1,041,555

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gary Patou”): 64,901,660 for, 1,041,555 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 86% for, 1% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.6% of the shares they voted on this item FOR (25,746,372 for, 82,409 against).

FOR 99.6%
FOR: 25,746,372 (99.7%)AGAINST: 82,409 (0.3%)
Largest asset managers voting on “Election of Directors: Gary Patou” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

8. Election of Directors: Gillian Cannon

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 65,895,891AGAINST: 47,324

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gillian Cannon”): 65,895,891 for, 47,324 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 87% for, 0.1% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.9% of the shares they voted on this item FOR (25,819,140 for, 9,641 against).

FOR 99.9%
FOR: 25,819,140 (100.0%)AGAINST: 9,641 (0.0%)
Largest asset managers voting on “Election of Directors: Gillian Cannon” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

9. Election of Directors: Ian Mortimer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 65,768,424AGAINST: 174,791

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Mortimer”): 65,768,424 for, 174,791 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 87% for, 0.3% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.9% of the shares they voted on this item FOR (25,819,140 for, 9,641 against).

FOR 99.9%
FOR: 25,819,140 (100.0%)AGAINST: 9,641 (0.0%)
Largest asset managers voting on “Election of Directors: Ian Mortimer” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

10. Election of Directors: Justin Gover

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 65,932,083AGAINST: 11,132

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Justin Gover”): 65,932,083 for, 11,132 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 87% for, 0.1% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.9% of the shares they voted on this item FOR (25,819,140 for, 9,641 against).

FOR 99.9%
FOR: 25,819,140 (100.0%)AGAINST: 9,641 (0.0%)
Largest asset managers voting on “Election of Directors: Justin Gover” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

11. Election of Directors: Pat Machado

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 63,197,819AGAINST: 2,745,396

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Machado”): 63,197,819 for, 2,745,396 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 84% for, 4% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 94% of the shares they voted on this item FOR (24,314,712 for, 1,514,069 against).

FOR 94%
FOR: 24,314,712 (94.1%)AGAINST: 1,514,069 (5.9%)
Largest asset managers voting on “Election of Directors: Pat Machado” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco0536,645 00Against
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse80,621272,377 00Against
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional0330,624 00Against
Jackson National62,295231,866 00Against
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

12. Election of Directors: Steven Gannon

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 65,709,645AGAINST: 233,570

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven Gannon”): 65,709,645 for, 233,570 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 87% for, 0.4% against (87% of the company cast a for/against vote).

The 69 asset managers below cast 99.9% of the shares they voted on this item FOR (25,819,140 for, 9,641 against).

FOR 99.9%
FOR: 25,819,140 (100.0%)AGAINST: 9,641 (0.0%)
Largest asset managers voting on “Election of Directors: Steven Gannon” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity6,271,4330 00For
Capital Group5,156,6660 00For
Vanguard2,815,4040 00For
BlackRock1,462,2300 00For
T. Rowe Price824,8880 00For
Federated Hermes734,9000 00For
TimesSquare Capital Management, LLC649,6780 00For
Lord Abbett621,4560 00For
DRIEHAUS MUTUAL FUNDS578,4300 00For
Bridge Builder Trust557,4840 00For
Invesco536,6450 00For
AllianceBernstein466,6170 00For
Prudential/PGIM421,7290 00For
Loomis Sayles399,7720 00For
Brinker Capital Destinations Trust370,2420 00For
Brighthouse343,3579,641 00For
Altium Capital Management LP348,0000 00For
AB DISCOVERY GROWTH FUND, INC.334,5280 00For
Dimensional330,6240 00For
Jackson National294,1610 00For
JANUS INVESTMENT FUND250,4830 00For
Putnam238,6700 00For
HARBOR FUNDS160,8890 00For
Equitable141,2190 00For
Russell Investments115,3860 00For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

13. Approve, on an advisory basis, the compensation of the Corporation's anmed executive officers

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

97% Majority: yes · of votes cast

FOR 97%
FOR: 63,950,064AGAINST: 1,979,402

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay").”): 63,950,064 for, 1,979,402 against, per its Form 8-K filed 2024-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 75,459,681 outstanding shares: 85% for, 3% against (87% of the company cast a for/against vote).

The 2 asset managers below cast 100% of the shares they voted on this item FOR (47,756 for, 0 against).

FOR 100%
FOR: 47,756 (100.0%)
Largest asset managers voting on “Approve, on an advisory basis, the compensation of the Corporation's anmed executive officers” at XENON PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Orion Porfolio Solutions, LLC23,8780 00For
Orion Portfolio Solutions, LLC23,8780 00For

Largest XENON PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of XENON PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 75,459,681 shares outstanding at the time of that meeting.

Top XENON PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Fidelity 17.05%
2Capital Group 13.67%
3Avoro Capital Advisors LLC 5.56%
4Wellington 4.84%
5DRIEHAUS CAPITAL MANAGEMENT LLC 4.26%
6Vanguard 3.81%
7Polar Capital Holdings Plc 3.32%
8Paradigm Biocapital Advisors LP 3.24%
9T. Rowe Price 2.95%
10COMMODORE CAPITAL LP 2.87%

Reported XENON PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

XENON PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 11.82% 13F
Avoro Capital Advisors LLC 7.51% DEF14A
FMR LLC 7.50% DEF14A
BlackRock 6.32% 13F
Driehaus Capital Management LLC 5.76% DEF14A
Entities affiliated with Wellington Management Group LLP 5.52% DEF14A
Wellington Management 5.20% 13F
Capital International 3.28% 13F
JPMorgan Chase 1.85% 13F
Citadel Advisors 1.73% 13F

Percentages above are of 75,459,681 shares outstanding, as reported by XENON PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from XENON PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At XENON PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-04, in the 2023-2024 proxy season, 224 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,526 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: XENON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-05.

XENON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.